USP7 disrupts the equilibrium of the p53-dependent MDM2 axis, leading to the proteasomal degradation of p53 and ultimately decreasing the expression of PD-L1 on the surface of tumor cells.120, 121, 122 Several USP7 inhibitors are currently in preclinical trials and further studies are required. This evidence concerns the gene TP53 and neoplasm.